N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer
Both
Lung Cancer
Trial Information
Inclusion Criteria:
- At least 18 years of age
- Karnofsky Performance Status (KPS) 60% or more
- Undergoing antineoplastic chemotherapy for lung cancer
- Able to provide informed consent
Exclusion Criteria:
- Brain metastasis, stroke or major psychiatric diseases
- Active infection
- Severe heart disease
- Serious systemic diseases such as uncontrolled hypertension and diabetes mellitus
- Acupuncture therapy within the previous three months
- Communication disorder
- Unwillingness to participate in the trial
- Severe immunocompromised state (absolute neutrophils count < 1000/cubic mm)
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Outcome Measure:
Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline
Outcome Time Frame:
7-10 days during a rest period between chemotherapy cycles
Safety Issue:
No
Principal Investigator
Yun Seong Kim, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Pusan National University Yangsan Hospital
Authority:
Korea: Food and Drug Administration
Study ID:
KCRC-IRB-2011009 & L-2011-170
NCT ID:
NCT01408212
Start Date:
July 2011
Completion Date:
December 2012
Related Keywords:
- Lung Cancer
- Lung Neoplasms
Name | Location |
|---|
